Helen Torley joins Onyx Pharmaceuticals
Takes the position of executive vp and chief commercial officer
Torley reports to Anthony Coles, president and chief executive officer, and take responsibility for all commercial activities related to Nexavar and the potential launch of carfilzomib, the development of the company's European commercial organisation, and initiatives to grow business and capabilities in the US and Europe.
Before joining Onyx, Torley spent nine years at Amgen where she most recently served as vice president and general manager of the Bone Health Business Unit, after leading the company's Nephrology Business Unit for five years.
From 1997 to 2002, she held various senior management positions at Bristol Myers Squibb.
Torley began her industry career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, overseeing phase IIIb and IV clinical studies across all therapeutic areas, including oncology.
You may also like
Regulatory
![Early phase analytical strategy for biosimilars in a shifting regulatory landscape]()
Early phase analytical strategy for biosimilars in a shifting regulatory landscape
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Pharmaceutical
![Formulation freedom in clinical development: Why Fill2Weight matters]()
Formulation freedom in clinical development: Why Fill2Weight matters
As drug discovery accelerates, especially for poorly soluble small‑molecule compounds, formulation teams increasingly modify particle size, morphology and structure to improve dissolution in the body. This is precisely where 3P innovation’s proprietary Fill2Weight Gravimetric Powder Filler becomes a game‑changer
Research & Development
![Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline]()
Alzheimer’s Association launches $100m trial combining lifestyle changes and GLP-1s to prevent cognitive decline
The global study builds on US POINTER trial findings, testing whether adding a metabolism-targeting drug to structured lifestyle programmes can further reduce cognitive decline risk in at-risk older adults during a three-year period
Pharmaceutical
![Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate]()
Teva and Polpharma Biologics sign global licensing deal for Ocrevus biosimilar candidate
The agreement will expand Teva’s biosimilars pipeline, with the company securing exclusive commercialisation rights for Polpharma Biologics’ proposed ocrelizumab biosimilar across key global markets
Pharmaceutical
![Pouching solutions for sterile and moisture-sensitive devices]()
Pouching solutions for sterile and moisture-sensitive devices
Sterile pouch loading and sealing is far more complex than a conventional packaging operation: When the pouch itself becomes the primary sterile barrier (and the product is filled aseptically) the packaging process must be engineered with the same level of care as the filling operation itself